Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of LY2127399 With Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma (Japan)
jRCT2080221743Phase 1
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of tabalumab in multiple myeloma (MM) (2 arms), sponsored by Eli Lilly and Company.
02
Drugs
tabalumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080221743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221743.